ALX Oncology Holdings Inc (ALXO) Quote

ALXO............................................................................................p/m

ALXO.................................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

alxo......................https://stockcharts.com/h-sc/ui?s=alxo&p=W&b=5&g=0&id=p86431144783

ALXO...........................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

ALXO..............................https://stockcharts.com/h-sc/ui?s=ALXO&p=W&b=5&g=0&id=p86431144783

ALXO new 52 week low

ALXO under $2

ALXO under $3

ALXO new 52 week low

Fast tracked

Loaded and halted 20%short. Hahahah

ALXO under $10

ALXO new 52 week high

ALXO new 52 week high

ALXO new 52 week high

ALXO $15.23 +2.20 (+16.88%)

Well, there's the few % I was thinking of but why get off here? There's no sign of the drift up stopping...

https://stockcharts.com/h-sc/ui?s=ALXO

https://finance.yahoo.com/news/alx-oncology-holdings-inc-alxo-214706863.html

Jefferies Upgrades ALX Oncology Holdings to Buy, Raises Price Target to $18
BENZINGA 6:27 AM ET Dec-08-2023
Jefferies analyst Michael Yee upgrades ALX Oncology Holdings (ALXO.NaE) from Hold to Buy and raises the price target from $8 to $18.

Form SC 13D/A ALX ONCOLOGY HOLDINGS Filed by: LSV Associates, LLC
10K WIZARD
6:00 AM ET Dec-20-2023
http://archive.fast-edgar.com/20231220/AHBYD22D8M2232ZZ272F2WZZHEUJZ2Z2Z252
Filed on: December 20, 2023

Refinitiv/Verus upgrades ALX ONCOLOGY HOLDINGS ORD SHS from SELL to HOLD.
INVESTARS ANALYST ACTIONS - PUBLIC - 1:13 PM ET Nov-27-2023
On November 27, 2023 Refinitiv/Verus upgraded ALX ONCOLOGY HOLDINGS ORD SHS from SELL to HOLD.

ALXO In at $14.86 +1.83 (+14.04%)
As of Dec-22-202311:12:41 AM ET

https://stockcharts.com/h-sc/ui?s=ALXO

See if I might catch a few % of this drift up.

Good Phase 2 Interim Results
Upgrade
Short squeeze
Significant add by stakeholder

ALXO new 52 week high
Compare to Marathon Digital

This is a weird one has more cash than market cap after closing this and Cantor Fitzgerald moves price target up to $23.0 and UBS to $27.00

Agreed and volume is not sustainable. Daily showing $5.04 thinking closes gap @ $6.00

Offering watch

Any offering yet

$ALXO in at $7.55 bottom bounce

Premerket party chee chee cheeee

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
-- Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors

-- Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment

-- Company to host conference call and webcast today at 8:00 AM EDT

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced positive prespecified interim Phase 2 data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating evorpacept, the Company’s CD47 blocking therapeutic, in combination with trastuzumab, CYRAMZA® (ramucirumab) and paclitaxel for the treatment of patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer. This prespecified interim analysis represents results from 54 randomized patients with second and third line gastric/GEJ cancer, including a meaningful number of patients previously treated with ENHERTU® (trastuzumab deruxtecan) and checkpoint inhibitors. Patients were treated with evorpacept at 30 mg/kg every two weeks, mirroring the treatment cycle of trastuzumab, CYRAMZA and paclitaxel.

Phase 2 ASPEN-06 Interim Analysis Results:

A confirmed overall response rate (“ORR”) of 52% was demonstrated for evorpacept in combination with trastuzumab + CYRAMZA + paclitaxel compared to 22% for the control group of trastuzumab + CYRAMZA + paclitaxel.
Median duration of response (“mDOR”) was not reached for the evorpacept combination treatment arm compared to 7.4 months for the control group.
The safety profile of evorpacept was consistent with previous clinical trials and was well-tolerated.
These interim results compare favorably to the efficacy reported for CYRAMZA + paclitaxel in the RAINBOW study (ORR of 28% and mDOR of 4.4 months), which is the regulatory benchmark and global standard of care for second line gastric/GEJ cancer.
“The ASPEN-06 clinical trial validates the potential of evorpacept both in solid tumors and in combination with anti-cancer antibodies and these data highlight the drug’s potential as a first-in-class foundational immunotherapy,” said Sophia Randolph, M.D., Ph.D., Chief Medical Officer, ALX Oncology. “We are highly encouraged by these initial randomized efficacy and safety results in gastric cancer that build upon the activity previously seen in our first-in-human study and represent the first positive randomized clinical trial data presented for any CD47 blocker. In addition, ASPEN-06 is the first global randomized study in HER2-positive gastric cancer where prior KEYTRUDA® (pembrolizumab) and ENHERTU were allowed. We look forward to reporting the final analysis from the ongoing Phase 2 ASPEN-06 study in Q2 2024 and plan to initiate the Phase 3 portion of ASPEN-06 in late 2024.”

“These data in gastric cancer represent the first positive initial result in a randomized trial setting of blocking the CD47 immune checkpoint pathway with a CD47 blocker that has an inactive Fc effector function in order to treat patients living with advanced gastric cancer,” said Keun Wook Lee, M.D., Ph.D., Professor at Seoul National University College of Medicine and ASPEN-06 Principal Investigator. “Patients with advanced disease face poor outcomes following progression on initial treatment with HER2-directed therapy. Evorpacept could represent a breakthrough in therapy and a potential paradigm shift in the gastric cancer care continuum.”

Upcoming Clinical Milestones for Evorpacept’s Development Pipeline

1H 2024 Non-Hodgkin Lymphoma - Phase 1b investigator-sponsored trial with rituximab + lenalidomide top line results (Q1/Q2 2024)Gastric/GEJ Cancer – Phase 2 ASPEN-06 randomized top line final results (Q2 2024)
2H 2024 Head and Neck Squamous Cell Carcinoma – Phase 2 ASPEN-03 with KEYTRUDA randomized top line resultsHead and Neck Squamous Cell Carcinoma – Phase 2 ASPEN-04 with KEYTRUDA + chemotherapy randomized top line resultsGastric/GEJ Cancer – Phase 3 ASPEN-06 study initiationUrothelial Carcinoma – Phase 1b ASPEN-07 with PADCEV® (enfortumab vedotin-ejfv) top line resultsBreast Cancer – Phase 1b I-SPY study with ENHERTU top line results
Conference Call on October 3 at 8:00 am EDT

The Company will host a conference call and webcast today at 8:00 AM EDT that will feature ASPEN-06 investigator Dr. Josep Tabernero, Director of the Vall d’Hebron Institute of Oncology and Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona, Spain and past President of the European Society of Medical Oncology.

To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally) at least 10 minutes prior to the start time and refer to conference ID 7797378. The link to the live webcast of the conference call will be posted in the News & Events section (see “Events”) of the Company’s website at www.alxoncology.com. An archived replay will be accessible for 90 days following the event.

About the ASPEN-06 Study

ASPEN-06 is a randomized Phase 2 (open-label) / Phase 3 (double-blinded), multi-center international study of patients with second or third line metastatic HER2-overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy. While trastuzumab is currently approved in combination with cisplatin or capecitabine for HER2-positive gastric/GEJ cancers, it is not yet approved with the standard-of-care of CYRAMZA + paclitaxel. The Phase 2 portion of the ASPEN-06 study is designed to enroll 122 patients who have progressed on, or after prior HER2-directed therapy and fluoropyrimidine and/or platinum-containing regimens. To determine the activity of evorpacept + trastuzumab + CYRAMZA + paclitaxel, in the Phase 2 portion of ASPEN-06, patients are randomized to receive either a four-drug combination regimen (evorpacept + trastuzumab + CYRAMZA + paclitaxel) or a three-drug combination regimen (trastuzumab + CYRAMZA + paclitaxel). This design enables the assessment of evorpacept’s contribution to the standard of care plus trastuzumab and to global standard of care, CYRAMZA + paclitaxel. Should the Phase 2 portion of the trial demonstrate proof of concept, the trial will progress to the Phase 3 portion where the evorpacept containing four-drug regimen will be tested against the two-drug global standard of care of CYRAMZA + paclitaxel.

About Gastric Cancer and Gastroesophageal Junction Cancer

Gastric cancer (“GC”) begins in the cells lining the inner wall of the stomach and spreads through the outer layers and eventually the body as it grows. GC is the fifth most common cancer worldwide and the third leading cause of cancer mortality as reported by GLOBOCAN. The American Cancer Society estimates there will be 26,500 newly diagnosed cases of GC at all stages in the U.S. in 2023, and approximately 17 percent of all GC patients have HER2-positive disease. The five-year survival rate is only 5.5 percent for those patients diagnosed with metastatic disease. GC is more common in East Asian countries, with incidence rates 4 to 10 times higher than in the U.S.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a h

$ALXO Bueler Bueler! Lol

$ALXO Chaching!

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Source: GlobeNewswire Inc.

ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer

Right... !! is probably more like it. Absolute beast. TRIL may have the better CD47 though.

Didn’t mean “??” Lol. Whoops.

??

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159536483

??

$1.5mil trade x $43

PR: “ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma”

https://ir.alxoncology.com/node/6471

ALXO moving on air.

Company Website: https://alxoncology.com

“ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.”

ALXO moving

First

ALXO